Cosentyx (secukinumab) is a brand-name injection prescribed for plaque psoriasis and certain types of arthritis. It works to treat these conditions by slowing down an overactive immune system.

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

Credit: Novartis The IV formulation is supplied as a 125mg/5mL solution in a single-dose vial and requires dilution prior to administration. The Food and Drug Administration (FDA) has approved an ...

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy. The ...